WBC Infection Imaging: In-111 & Tc-99m HMPAO

Radiolabeled autologous white blood cell (WBC) scintigraphy remains one of nuclear medicine's most specific tools for finding occult infection and inflammation, and the choice between technetium-99m (Tc-99m) hexamethylpropyleneamine oxime (HMPAO) and indium-111 (In-111) oxine is fundamentally a physics and workflow decision. Photon energy, half-life, labeling efficiency, image quality, and radiation burden all differ between the two agents, and the in-vitro labeling quality-control steps are what separate a diagnostic study from a nondiagnostic one.¹²³

Because the labeled cells are the patient's own leukocytes migrating to sites of active infection, WBC scintigraphy offers specificity that anatomic imaging often cannot, particularly for prosthetic-joint, diabetic-foot, and abdominal infection where structural imaging is ambiguous.³

Introduction

Labeled leukocyte imaging works on a simple biological premise: activated white blood cells accumulate at sites of infection and inflammation. If a sample of the patient's leukocytes can be labeled with a gamma-emitting radionuclide and reinjected, a gamma camera can map where those cells collect — localizing an infection that anatomic imaging may miss or misattribute to post-surgical change, hardware artifact, or edema.³

Two radiopharmaceuticals dominate practice. Tc-99m HMPAO-labeled leukocytes exploit the excellent imaging characteristics of Tc-99m: a 140 keV photon ideally matched to modern gamma cameras, a convenient six-hour half-life, wide availability, and a comparatively low radiation burden. In-111 oxine-labeled leukocytes trade image quality for a long half-life that enables 24-hour delayed imaging and dual-isotope studies. Understanding the physics behind that trade-off — and rigorously controlling the labeling process — is what makes the study reliable.¹²³

This guide covers the radionuclide physics, the labeling and quality-control workflow, the clinical impact of the Tc-99m-versus-In-111 choice, practical optimization tips, and the regulatory context for a WBC labeling program.

Topic Explanation

The biological and physical basis

WBC scintigraphy images function, not anatomy. After a blood sample is drawn, the leukocytes are separated, incubated with a lipophilic radiolabel that crosses the cell membrane and becomes trapped intracellularly, washed to remove unbound activity, and reinjected. Over the following hours the labeled cells distribute through the reticuloendothelial system and migrate to any focus of active infection or sterile inflammation, where they accumulate above background.¹²

For Tc-99m HMPAO, the lipophilic complex diffuses into the leukocyte and is converted to a hydrophilic form that is retained inside the cell. For In-111 oxine, the neutral lipid-soluble In-oxine complex penetrates the membrane, and the indium then binds firmly to cytoplasmic components while the oxine carrier is released.¹²

Why the radionuclide choice is a physics decision

Tc-99m and In-111 differ in every property that matters for imaging. Tc-99m emits a single 140 keV photon, has a 6.0-hour half-life, and is available from an on-site generator. In-111 emits two higher-energy photons at 171 keV and 245 keV, has a much longer half-life of about 67 hours, and must be ordered in advance. The longer half-life of In-111 permits delayed imaging out to 24 hours and beyond, but the higher photon energies and the biodistribution of In-oxine-labeled cells deliver a substantially higher radiation dose, particularly to the spleen, and produce planar and SPECT images of lower quality than Tc-99m.¹²⁸

Key Technical Principles

Comparing the two labeled-leukocyte agents

The table summarizes the physical and practical differences that drive the choice between the two agents.¹²³⁶

The practical consequence is that Tc-99m HMPAO is the workhorse for most indications, while In-111 oxine is reserved for situations where its longer half-life or minimal bowel excretion is specifically advantageous.²³

Labeling efficiency: the central quality metric

The most important in-vitro quality-control measurement is the labeling efficiency (LE) — the fraction of radioactivity bound to the cells rather than remaining free in the supernatant. After incubation and centrifugation, the activity in the cell pellet and in the supernatant are measured separately, and:

As a worked example, suppose the pellet measures 42 MBq and the discarded supernatant measures 18 MBq after an In-111 oxine labeling:

For In-111 oxine, a labeling efficiency of 50–80% is expected, and process validation targets an LE greater than 60%. If LE falls below 50%, further checks — microscopic inspection and a trypan blue viability test — should be performed before deciding whether to release the preparation.²

Cell integrity and release criteria

A high LE is necessary but not sufficient: the cells must also be viable and undamaged. The EANM labeling guidelines set concrete release criteria. On the trypan blue exclusion test, a preparation with more than 4% dead (blue-stained) cells should not be released. Cell efflux — the radioactivity that leaks back out of the cells within one hour — should be under 5% (radiochemical purity above 95%). Contamination limits in the final suspension are an erythrocyte-to-WBC ratio below 3 and a platelet-to-WBC ratio below 1. At least 2 × 10⁸ leukocytes are needed to achieve good labeling efficiency.²

Damaged cells fail in a physically visible way: they get trapped in the pulmonary microvasculature. In-vivo lung images acquired about 30 minutes after injection should show nearly complete clearance of lung activity; persistent diffuse lung uptake indicates cell damage during labeling, and the study should be interpreted with caution. A quantitative liver-to-spleen ratio, in which spleen activity should normally exceed liver activity, is a secondary check for cell damage.²

Radiation dosimetry and the critical organ

The radiation burden of labeled-leukocyte imaging is dominated by where the cells accumulate. After reinjection, most of the activity is taken up by the reticuloendothelial system — spleen, liver, and bone marrow. For In-111 oxine leukocytes, the guidelines describe an initial uptake of about 60% of the activity in liver, spleen, marrow, and other tissues, settling to roughly 20% liver, 25% spleen, 30% marrow, and 25% elsewhere, with very slow clearance from liver and spleen and minimal urinary or fecal excretion. Because the spleen concentrates a large fraction of the activity and receives self-dose from the higher-energy In-111 photons and internal conversion electrons, it is the critical organ, and this — combined with the long physical half-life — is why the administered activity is kept to only 10–18.5 MBq.²

Tc-99m HMPAO leukocytes deliver a lower effective dose despite the far higher administered activity, because the six-hour half-life limits the time-integrated activity and the 140 keV photon is less energetic. This favorable dosimetry, together with superior image quality, is a large part of why Tc-99m HMPAO has become the default agent for most indications, reserving the higher-dose In-111 study for the specific situations where its properties are needed.¹²

Dual-isotope and energy-window considerations

In-111's two photopeaks at 171 keV and 245 keV are well separated from the 140 keV peak of Tc-99m, which is what makes dual-isotope studies practical. When a leukocyte study is combined with a Tc-99m sulfur-colloid marrow scan to distinguish infection from normal or displaced marrow, In-111 leukocytes and the Tc-99m marrow agent can be imaged simultaneously using separate energy windows without spectral overlap corrupting either image. Correct energy-window setup is therefore a genuine physics prerequisite for these protocols: windows must be centered on the correct photopeaks with appropriate widths, and the camera's multi-window performance verified, or the marrow-subtraction comparison that drives the diagnosis becomes unreliable.²³

Imaging protocol and timing

The imaging protocol exploits the kinetics of leukocyte migration. For Tc-99m HMPAO leukocytes, early images can be acquired within 30 minutes to 1 hour, delayed images at 3–4 hours, and late images at 20–24 hours, with SPECT or SPECT/CT added for anatomic localization. Because a true infection accumulates labeled cells over time while normal or vascular activity does not, the diagnostic reading compares the delayed and late images: increasing focal activity between time points supports infection.³ Reliable camera performance underpins all of this — see our guides to gamma camera uniformity QC and SPECT/CT quality control.

Clinical Impact

WBC scintigraphy earns its place where anatomic imaging is ambiguous and specificity is at a premium. Classic indications include suspected prosthetic-joint infection, osteomyelitis complicating the diabetic foot, fever of unknown origin, vascular graft infection, and inflammatory bowel disease.⁷ In these settings, CT and MRI can show fluid, edema, or hardware artifact that is difficult to attribute to infection specifically, whereas labeled leukocytes concentrate where neutrophils are actually accumulating.³

The Tc-99m-versus-In-111 choice has direct clinical consequences. For most musculoskeletal and soft-tissue infection, Tc-99m HMPAO's superior image quality and SPECT/CT capability make it the default. For prosthetic-joint and osteomyelitis questions, leukocyte imaging is frequently paired with a Tc-99m sulfur-colloid marrow scan; because the labeled leukocytes and marrow agent can be separated by energy window, In-111 leukocytes combine cleanly with a Tc-99m marrow study in a dual-isotope protocol. For abdominal infection and inflammatory bowel disease, In-111 oxine's minimal bowel excretion avoids the confounding gut activity seen with Tc-99m HMPAO, which is excreted through the hepatobiliary system into bowel.²³

Because the labeled cells are patient-specific and the labeling is labor-intensive, a nondiagnostic study caused by poor labeling is costly: the patient must be recalled, re-drawn, and re-imaged, delaying a treatment decision. That is why the labeling quality-control steps are not bureaucratic box-checking — they directly protect the diagnostic value of the study. For the analogous purity discipline in kit radiopharmaceuticals, see our guide to radiochemical purity and thin-layer chromatography QC.

Practical Optimization Tips

Protect labeling efficiency at every step

Labeling efficiency is fragile. Draw blood slowly through a needle of at least 20 gauge to avoid shear damage, use the correct anticoagulant and sedimentation agent, avoid excessive centrifugal force that increases platelet contamination, and keep the cells in a physiological medium. Handle the cells gently — most low-LE and cell-damage problems trace back to rough technique somewhere in the separation.¹²

Reinject promptly

Labeled leukocytes should be reinjected as soon as possible, and no later than one hour after labeling, to limit radiation damage to the cells and loss of function. A preparation held too long can show reduced migration and increased lung retention.²

Run the routine QC every time

Make visual inspection for clumps and clots, and the labeling-efficiency measurement, standard on every preparation. If clumps cannot be dispersed, do not inject. Reserve the more time-consuming tests — trypan blue viability, cell subset recovery, efflux — for validation and periodic checks, but never skip the routine two.²

Match the agent to the question

Choose Tc-99m HMPAO for most indications and when SPECT/CT resolution matters; choose In-111 oxine when 24-hour delayed imaging, dual-isotope marrow subtraction, or abdominal and inflammatory bowel imaging is the goal. Selecting the agent before drawing blood avoids wasted labeling.²³

Guard patient identity and blood safety

Because the procedure handles the patient's own blood and reinjects it, the two non-negotiables are blood-borne-pathogen precautions for the operator and absolute prevention of cross-labeling. Label every syringe and tube with patient identifiers, avoid simultaneous labeling of multiple patients unless a closed system is used, and verify identity before reinjection.¹²

Support imaging with camera QC

The diagnostic yield of a technically perfect labeling can still be lost to a poorly performing camera. Keep gamma camera uniformity, energy-window setup, and SPECT/CT calibration current, and use dual-energy windows correctly for In-111's two photopeaks and for dual-isotope protocols.³

Regulatory Considerations

A WBC labeling program sits at the intersection of radioactive-material regulation and blood-product handling. The radiopharmaceutical side is byproduct material governed by the NRC or an Agreement State:

• 10 CFR Part 20 — Standards for Protection Against Radiation, setting occupational and public dose limits and the ALARA framework for handling the radionuclides.⁴
• 10 CFR Part 35 — Medical Use of Byproduct Material, governing authorized use, written directives where applicable, dose calibrator and survey requirements, and the Radiation Safety Officer's responsibilities.⁵

The labeling procedure itself is standardized internationally. The EANM guidelines for labeling leukocytes with Tc-99m HMPAO and with In-111 oxine specify the aseptic technique, quality-control tests, and release criteria referenced throughout this guide, and the EANM/SNMMI procedural guideline covers image acquisition and interpretation. Aseptic handling is essential because autologous cells cannot be sterilized after labeling.¹²³

Agreement States administer equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States, while Washington, DC and Delaware are regulated directly by the NRC. In Florida, medical use of radioactive material is administered by the Florida Department of Health, Bureau of Radiation Control, under Chapter 64E-5, Florida Administrative Code. Always confirm requirements with the authority having jurisdiction.

Frequently Asked Questions (FAQs)

What is radiolabeled WBC scintigraphy?

It is a nuclear medicine study in which a sample of the patient's own white blood cells is separated, labeled with a radiotracer — most often Tc-99m HMPAO or In-111 oxine — reinjected, and imaged as the cells migrate to sites of infection or inflammation. Because activated leukocytes accumulate at infection foci, the labeled cells localize the process.

Should I use Tc-99m HMPAO or In-111 oxine?

Tc-99m HMPAO gives higher photon flux and better image and SPECT quality, lower radiation burden, and same-day imaging, so it is the more common choice. In-111 oxine has a longer half-life that supports 24-hour delayed imaging, does not interfere with a Tc-99m bone marrow scan, and is preferred for abdominal and inflammatory bowel disease imaging because it has minimal bowel excretion.

What is labeling efficiency and why does it matter?

Labeling efficiency is the fraction of radioactivity bound to the cells rather than left in the supernatant. Low labeling efficiency wastes activity, degrades image quality, and can signal cell damage. For In-111 oxine a labeling efficiency of 50 to 80 percent is expected, and validation targets exceed 60 percent.

How soon are the images acquired?

For Tc-99m HMPAO labeled leukocytes, early images may be taken within 30 minutes to 1 hour, delayed images at 3 to 4 hours, and late images at 20 to 24 hours, with SPECT or SPECT/CT as needed. Comparing delayed and late images helps distinguish true infection, which accumulates over time, from normal or vascular activity.

Is WBC labeling a radiation safety and blood-handling risk?

Yes on both counts. The technologist handles the patient's blood, so universal precautions, gloves, and needle-stick discipline are essential, and mislabeling one patient's cells for another must be prevented by strict identity checks. The radiopharmaceutical handling also follows standard nuclear medicine radiation safety and ALARA practice.

Who oversees the labeling and imaging quality?

The nuclear medicine physician and authorized user oversee clinical use, while a board-certified medical physicist supports camera and SPECT/CT quality control, quantitative and dosimetry questions, and radiation safety. Radiopharmacists or trained technologists perform the labeling under a qualified person's responsibility.

Key Takeaways

• WBC scintigraphy images function — leukocyte migration to infection — giving specificity that anatomic imaging often cannot.
• The Tc-99m HMPAO versus In-111 oxine choice is a physics trade-off: photon energy, half-life, image quality, and radiation burden all differ.
• Tc-99m HMPAO (140 keV, 6 h, 370–740 MBq) is the workhorse; In-111 oxine (171/245 keV, ~67 h, 10–18.5 MBq) is reserved for 24-hour imaging, dual-isotope marrow studies, and abdominal or bowel disease.
• Labeling efficiency is the central QC metric; In-111 oxine targets 50–80%, with validation above 60%, plus viability, efflux, and contamination-ratio criteria.
• Imaging compares delayed (3–4 h) and late (20–24 h) images so true infection, which accumulates over time, stands out from background.
• Blood handling and patient-identity discipline are as important as radiation safety, because autologous cells cannot be sterilized after labeling.

Conclusion

Radiolabeled WBC scintigraphy endures because it answers a question anatomic imaging often cannot: where is the infection actually active? Realizing that value depends on two things a physicist and radiopharmacy team can control — choosing the right radionuclide for the clinical question, and executing the labeling with disciplined quality control. When Tc-99m HMPAO and In-111 oxine are matched to the indication and the labeling meets its efficiency, viability, and purity criteria, the study delivers specific, actionable answers for some of the most difficult infection questions in medicine.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine departments across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with PET/CT and nuclear medicine physics, gamma camera and SPECT/CT quality control, dual-isotope protocol support, medical physicist consulting, and radiation safety training — delivered by board-certified medical physicists.

A strong labeled-leukocyte program is not only about the labeling bench. It is about aligning agent selection, quality control, camera performance, and interpretation so the study is diagnostic the first time.

Related Resources

• Gamma camera uniformity QC
• SPECT/CT quality control
• Radiochemical purity and TLC quality control
• Gamma camera collimator selection
• Nuclear medicine decontamination best practices
• PET/CT & nuclear medicine physics
• Medical physicist consulting

References

1. de Vries EFJ, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):842-848. doi:10.1007/s00259-010-1394-4. doi.org
2. Roca M, de Vries EFJ, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):835-841. doi:10.1007/s00259-010-1393-5. doi.org
3. Signore A, Jamar F, Israel O, Buscombe J, Martin-Comin J, Lazzeri E. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. Eur J Nucl Med Mol Imaging. 2018;45(10):1816-1831. doi:10.1007/s00259-018-4052-x. doi.org
4. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
5. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
6. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
7. Society of Nuclear Medicine and Molecular Imaging. Procedure Standards and Practice Guidelines. Reston, VA: SNMMI. snmmi.org
8. National Institute of Standards and Technology. Radionuclide Half-Life Measurements and Decay Data. nist.gov